Document is current
Any future updates will be listed below
-
Authors
Dominguez-Valentin, Mev http://orcid.org/0000-0001-7856-0057
Seppälä, Toni T.
Sampson, Julian R.
Macrae, Finlay
Winship, Ingrid
Evans, D. Gareth
Scott, Rodney J.
Burn, John
Möslein, Gabriela
Bernstein, Inge
Pylvänäinen, Kirsi
Renkonen-Sinisalo, Laura
Lepistö, Anna
Lindblom, Annika
Plazzer, John-Paul
Tjandra, Douglas
Thomas, Huw
Green, Kate
Lalloo, Fiona
Crosbie, Emma J.
Hill, James
Capella, Gabriel
Pineda, Marta
Navarro, Matilde
Vidal, Joan Brunet
Rønlund, Karina
Nielsen, Randi Thyregaard
Yilmaz, Mette
Elvang, Louise Laurberg
Katz, Lior
Nielsen, Maartje
ten Broeke, Sanne W.
Nakken, Sigve
Hovig, Eivind
Sunde, Lone
Kloor, Matthias
Knebel Doeberitz, Magnus v
Ahadova, Aysel
Lindor, Noralane
Steinke-Lange, Verena
Holinski-Feder, Elke
Mecklin, Jukka-Pekka
Møller, Pål
-
Funding
Funding for this research was provided by:
Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007)
Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds (SAF2015-68016-R))
Kreftforeningen (contract 194751-2017)
Wilhelm Sander-Stiftung (2016.056.1)
- License Information
-
More Information
Article History
Received: 1 June 2019
Accepted: 11 September 2019
First Online: 14 October 2019
Ethics approval and consent to participate
: All reporting centers obtained informed consent for genetic testing and surveillance procedures. De-identified data was exported for the current study. No named registry needing approval was established for the current study.
: Not applicable.
: Toni Seppälä: a co-owner (20%) of Healthfund Finland Oy (educational and health care services in Finland, not related to patients or scope of this manuscript). Travel costs to a scientific meeting by Medtronic Finland.John Burn: a patent for high speed low cost tumor profiling pending to John Burn and QuantuMDx.All others: None declared.
